Inactive Instrument

Oxford Immunotec Global PLC

Equities

OXFD

GB00BGFBB958

Oxford Immunotec Global plc Reports Impairment Charges for the Fourth Quarter Ended December 31, 2018; Provides Revenue Guidance for the Year 2019

March 11, 2019 at 09:40 pm IST

Oxford Immunotec Global PLC provided revenue guidance for the year 2019. For the year, the company expects revenue of between $69 and $72 million.

For the fourth quarter ended December 31, 2018 the company reported impairment charges of $879,000 compared to $7,236,000 a year ago.

Latest news about Oxford Immunotec Global PLC

Oxford Immunotec Announces Use of T-SPOT®Discovery SARS-CoV-2 Kit	29/21/29	CI
Oxford Immunotec Global PLC will Change its Name to Oxford Immunotec Global Limited	09/21/09	CI
Oxford Immunotec Global PLC Announces Board Changes	09/21/09	CI
Oxford Immunotec Global PLC(NasdaqGM:OXFD) dropped from S&P Global BMI Index	08/21/08	CI
Oxford Immunotec Global PLC(NasdaqGM:OXFD) dropped from NASDAQ Composite Index	08/21/08	CI
PerkinElmer (UK) Holdings Limited completed the acquisition of Oxford Immunotec Global PLC.	08/21/08	CI
Oxford Immunotec Global PLC's Equity Buyback announced on January 7, 2019, has expired.	08/21/08	CI
Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection	05/21/05	CI
Oxford Immunotec Global : Plans to Market T Cell Immune Response Measurement Kit to COVID-19 in South Korea	09/21/09	MT
Oxford Immunotec Global PLC Enters into A Memorandum of Understanding Green Cross Medical Science Corp. to Market the T-SPOT Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea	08/21/08	CI
Oxford Immunotec Updates Their T-SPOT® Discovery SARS-Cov-2 Kit and Include New Panel to Detect T Cells Reactive to Endemic Coronaviruses	04/21/04	CI
Oxford Immunotec Global : Teams With Valneva on COVID-19 Vaccine Candidate Testing	14/21/14	MT
Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of Valneva’s VLA2001 COVID-19 Vaccine Candidate in a Phase I/II Clinical Study	13/21/13	CI
Sector Update: Health Care Stocks Add to Early Rise, Supported by Biotech Companies	08/21/08	MT
Sector Update: Modest Advance for Health Care Stocks Despite Larger Gains for Biotechnology Sector	08/21/08	MT
OXFORD IMMUNOTEC GLOBAL : JP Morgan Downgrades Oxford Immunotec Global to Neutral From Overweight, Keeps $22 Price Target	07/21/07	MT
OXFORD IMMUNOTEC GLOBAL : Piper Sandler Downgrades Oxford Immunotec Global to Neutral from Overweight, Adjusts Price Target to $22 from $24	07/21/07	MT
DJ Industrial : Wall Street Sees Upbeat Open as US Congress Certifies Biden's Win After Capitol Chaos	07/21/07	MT
PerkinElmer : to Acquire Oxford Immunotec for $591 Million	07/21/07	MT
PerkinElmer (UK) Holdings Limited entered into an agreement to acquire Oxford Immunotec Global PLC (NasdaqGM:OXFD for approximately $560 million.	07/21/07	CI
Transcript : Oxford Immunotec Global PLC - Analyst/Investor Day	17/20/17
Oxford Immunotec Global : Gets Approval for T-Cell Select Reagent Kit for Tuberculosis Testing in South Korea	10/20/10	MT
Oxford Immunotec Announces the Approval of the T-Cell Select™ Reagent Kit	10/20/10	CI
Oxford Immunotec Global : Signs Exclusive Distributor Agreement with Riken Genesis for SARS-CoV-2 Kit	02/20/02	MT
Oxford Immunotec Global PLC Signs Exclusive Distributor Agreement with Riken Genesis, to Market the T-SPOT Discovery SARS-CoV-2 Kit for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection in Japan	02/20/02	CI

Chart Oxford Immunotec Global PLC

Duration

Period

More charts

Company Profile

Oxford Immunotec Global PLC,is a diagnostics company. It is focused on developing and commercializing tests for under-served immune-regulated conditions. Its product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Tick-borne disease is the collective name for diseases passed to humans through the bite of an infected tick. Its diagnostic tests for tick-borne infections include multiple laboratory developed tests (LDTs). Its tick-borne disease tests utilize molecular methods (such as polymerase chain reaction) and techniques to prosecute the immune system. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease.

Sector

More about the company